Summit Therapeutics (SUMM)

 

SUMM Share PerformanceMore

52 week high269.75 11/09/17
52 week low111.00 25/01/18
52 week change 18.50 (10.42%)
4 week volume1,452,385 27/04/18
price196.00
price date1527077013
close200.00

Media for (SUMM)

Latest NewsMore

Summit Therapeutics plc : Notice of AGM

Notification of a company’s annual general meeting

Summit Therapeutics plc : Holding(s) in Company

Notification of major interests in shares

Summit Therapeutics plc : Total voting rights

Notification of a change in the total number of voting rights

Director Deals - Summit Therapeutics PLC (SUMM)

Prof Stephen Davies, Non Executive Director, exercised 17,500 shares in the company on the 23rd April 2018 at a price of 1.0...

Director Deals - Summit Therapeutics PLC (SUMM)

Barry Price, Non Executive Director, exercised 31,481 shares in the company on the 23rd April 2018 at a price of 1.00p. The D...

Summit Therapeutics plc : Director/PDMR Shareholding

Notification of issuers, persons discharging managerial responsibilities and their connected persons in respect of transactions conducted in their own account in shares of the issuer

Summit Therapeutics advances gonorrhoea treatment plans

Summit Therapeutics said it had advanced its studies of new antibiotic candidates for the treatment of gonorrhoea. The co...

Summit Highlights Discovery of New Mechanism Antibiotics for the Treatment of Gonorrhoea at ECCMID 2018

A statement giving an update on research (e.g. clinical trials)

Fundamental DataMore

EPS-44
Dividend yield0 %

Latest discussion posts More

  • Dilution

    So after todays press release all of the gain made following the previous press release has been wiped out in one foul swoop. It seems every time we get a decent rise in the ...
    14-Sep-2017
    scep
  • Re: NEW ARTICLE: Four AIM shares for a p...

    ps valid points raised. Sold these in two lots, 247 and 177 as could only see drift until 2018. C diff drug trying to break into an established market, always difficult ...
    6-Jul-2017
    bobsson
  • Re: NEW ARTICLE: Four AIM shares for a post-...

    The article referenced on Interactive Investor states that Summit Therapeutics has 2 potential treatments "both well down the road to becoming proven and commercial products". ...
    18-Jun-2017
    pharmaspecialist

Users' HoldingsMore

Users who hold Summit Therapeutics also hold..

Codes & Symbols

ISINGB00BN40HZ01
SymbolsSUMM, LSE:SUMM, SUMM.L, SUMM:LN, LON:SUMM, XLON:SUMM